Abstract

Periconceptional intake of folic acid prevents some neural tube defects (NTDs). Other nutrients may also contribute to NTD etiologies; a likely candidate is choline. Similar to folic acid, choline is involved in one-carbon metabolism for methylation of homocysteine to methionine. The authors investigated whether maternal periconceptional dietary intakes of choline and its metabolite betaine influence NTD risk. Data were derived from a case-control study of fetuses and infants with NTDs among 1989–1991 California births. In-person interviews were conducted with mothers of 424 NTD cases and with mothers of 440 nonmalformed controls. A standard 100-item food frequency questionnaire was used to assess nutrient intake. Dietary intakes of choline were associated with reduced NTD risks. Controlling for intake of supplemental folic acid, dietary folate, dietary methionine, and other covariates did not substantially influence risk estimates for choline. NTD risk estimates were lowest for women whose diets were rich in choline, betaine, and methionine. That is, for women whose intake was above the 75th percentile compared with below the 25th percentile for all three nutrients, the odds ratio was 0.17 (95% confidence interval: 0.04, 0.76). Study findings for dietary components other than folic acid offer additional clues about the complex etiologies of NTDs.

Received for publication December 5, 2003; accepted for publication February 10, 2004.

Maternal nutritional factors have been implicated in the etiologies of neural tube defects (NTDs). Foremost among these factors has been the role of periconceptional intake of folic acid in reducing risks of NTD-affected pregnancies (1, 2). Other nutrients and nutrition-related factors have also been observed to influence NTD risks. For example, increased intakes of methionine (3), zinc (4), vitamin C (5), dairy products (6), and vitamin B12 (7) have been associated with reduced NTD risks. Furthermore, increased intakes of sweets (8), maternal diabetes (9), maternal hyperinsulinemia (10), and prepregnancy obesity (1113) have been associated with elevated NTD risks.

In this study, we investigated the association of intakes of two additional nutrients, choline and its metabolite betaine, with risk of NTD-affected pregnancies. These nutrients, similar to folic acid, are involved in one-carbon (methyl donors) metabolism for methylation of homocysteine to methionine and are utilized for the synthesis of cell membrane phospholipids; choline is a precursor of the neurotransmitter acetylcholine (1416). Our motivation to investigate these two nutrients was based on previous observations implicating folate and methionine in NTD risk, nutrients that, in conjunction with choline, have an interdependence in the conversion of homocysteine to methionine (16, 17). Alterations in the methylation of homocysteine to form methionine have been implicated in the risk of NTD-affected pregnancies (18). In addition, inhibition of choline uptake and metabolism in mouse embryos results in NTDs (19). To our knowledge, choline and betaine have not been investigated previously for their potential association with human NTDs. Thus, we examined data from a large population-based case-control study to investigate whether women who had greater periconceptional dietary intakes of choline and betaine were at decreased risk of NTD-affected pregnancies.

MATERIALS AND METHODS

This study involving human subjects was approved by the California State Committee for the Protection of Human Subjects. Details of the population-based case-control study used in this analysis have been described previously (20).

Infants or fetuses with NTDs (anencephaly, spina bifida cystica, craniorachischisis, or iniencephaly) were ascertained by reviewing medical records, including ultrasonography, at all hospitals and genetics clinics for those infants/fetuses delivered in select California counties and whose mothers gave their residence as California. Eligible were singleton liveborn infants, fetal deaths, and fetuses prenatally diagnosed and electively terminated in the cohort of 708,129 births and fetal deaths occurring between June 1989 and May 1991. Ascertained were 653 singleton infants/fetuses with an eligible NTD diagnosis. Controls were randomly selected from each area hospital in proportion to the hospital’s estimated contribution to the total population of infants born alive in a given month from June 1989 to May 1991. Ascertained were 644 singleton infants born without a reportable congenital anomaly.

Women who spoke only languages other than English or Spanish or who had had a previous NTD-affected pregnancy were excluded, leaving 613 cases and 611 controls. In-person interviews were completed with mothers of 538 (87.8 percent) cases and of 539 (88.2 percent) controls an average of 4.9 months for cases and 4.6 months for controls after the actual or projected date of term delivery. Information was elicited from women about medical history, reproductive history, and activities associated with various lifestyles, primarily during the periconceptional period (6-month period from 3 months before to 3 months after conception).

A standard 100-item food frequency questionnaire was used to assess nutrient intake from diet (21). This instrument has been validated for use in epidemiologic studies (2224). Study women themselves completed the questionnaire (English or Spanish), with interviewers present to assist. Each woman was instructed to estimate her usual frequency and portion size of the food items she consumed during the 3 months before conception. Average daily intake of nutrients was computed by using the questionnaire’s software (21). Of the 1,077 women who completed an interviewer-administered questionnaire, 1,007 finished a food frequency questionnaire; of these, 916 provided data considered suitable on the basis of error checks built into the analytical software (21). The analytical program examined the data for a variety of errors to produce invalid data; more than half of the questionnaires dropped were because the number of foods selected for daily consumption was considered excessive. An additional 52 women who reported the use of food supplements such as SlimFast (SlimFast Foods Company, West Palm Beach, Florida) were excluded because of inadequate information to assess the choline or betaine content of these supplements. Of the 864, 424 were mothers of NTD cases and 440 were mothers of controls. The 424 cases included 161 with anencephaly, 242 with spina bifida, and 21 with other NTD phenotypes.

The choline and betaine composition of individual foods was added to the food frequency questionnaire’s nutrient database by using values published recently by Zeisel et al. (25, 26). In general, food items in the food frequency database corresponded well with food items in the published food list (25), except for the absence of values for breakfast cereals from the food list. (Breakfast cereals were assigned choline and betaine values obtained from unpublished data from S. Zeisel, December 2003.) Choline and betaine values were adopted directly from the Zeisel et al. (25) food list when there was a 1:1 correspondence.

The food list includes 145 food items and the food frequency database 207. For foods in the database that did not have a direct correspondence, we assigned choline/betaine values associated with nutritionally comparable foods. For example, for “limas, black-eyed peas,” choline and betaine values for “navy beans” were assigned. Those few foods for which no nutritionally comparable food was found (e.g., olives, coconut milk) were not assigned choline/betaine values. Foods that contained no appreciable amount of choline or betaine were assigned zero values for choline and betaine (e.g., sugar).

For food items from the food frequency questionnaire composed of multiple foods, we made assignments based on the derivation of nutrient values from National Health and Nutrition Examination Survey food consumption values (G. Block (developer of the questionnaire), University of California, personal correspondence, 2003). That is, on the basis of these other data, if frequency of consumption of one of the items was considered much higher than for other items in the group, for example, oranges in the “oranges, grapefruit, tangerines” group, that item was selected to represent the group and the choline/betaine values were assigned for that item. If frequency of consumption of the items in the group was considered approximately equal, choline and betaine values for the contributing items were averaged (e.g., “other snacks, crackers, chips” = one third wheat crackers, one third corn chips, one third potato chips). Assignment of choline and betaine values to mixed dishes in the food frequency database, without a comparable mixed dish on the Zeisel et al. (25) food list, was based on the proportional contribution of individual food components in the recipe. The recipe was confirmed by the originator of the food frequency questionnaire (G. Block, 2003) based on her knowledge of the original National Health and Nutrition Examination Survey food item recipe. All choline and betaine values were assigned masked to case and control status. We computed women’s average daily intakes of choline and betaine by considering portion size and frequency of consumption of each food item.

NTD risk was estimated by using logistic regression models. Odds ratios and their 95 percent confidence intervals were computed to summarize the potential influence of several possible risk factors. Models were constructed to assess effects associated with continuous intake levels of choline and betaine. Models were also constructed in which intake levels were considered as quartile cutpoints. Intakes for mothers of controls were used to establish quartile categories of intake of each measure, with the lowest quartile as reference. Considered covariates in the analyses were maternal race/ethnicity (Latina, foreign born; Latina, US born; White, non-Latina; Black; other), education (<high school graduate, high school graduate, >high school graduate), height (meters), prepregnant weight (kilograms), energy intake (kilocalories/day), dietary folate intake (micrograms/day), dietary methionine intake (milligrams/day), and periconceptional multivitamin supplementation (none, use in the 3 months before conception, beginning use in the 3 months after conception). The frequencies or mean values of these data are displayed in table 1. We added daily folic acid intake from vitamin supplements in the period 3 months before conception to daily folate intake from diet also for the period 3 months before conception to estimate “total” folate intake from both sources. However, the addition of these two sources of intake did not account for known differences in bioavailability between supplemental folic acid and dietary folate. All analyses were performed by using the Statistical Analysis System (SAS) (27).

RESULTS

Decreased risks of NTD-affected pregnancies were found for higher periconceptional intakes of choline for all NTDs as well as for spina bifida and anencephaly separately (table 2). This pattern was observed whether intakes were analyzed as continuous or discrete measures (quartiles). We adjusted for maternal prepregnant weight, height, education, race/ethnicity, periconceptional vitamin use, dietary folate intake, dietary methionine intake, and total energy intake. These adjusted risks did not differ substantially from their unadjusted counterparts. That is, for the three increasing choline intake quartiles relative to the lowest quartile, odds ratios for NTDs were 0.63 (95 percent confidence interval (CI): 0.42, 0.99), 0.65 (95 percent CI: 0.39, 1.07), and 0.51 (95 percent CI: 0.25, 1.07), respectively.

We also observed decreased risks of NTD-affected pregnancies for higher periconceptional intakes of betaine for all NTDs as well as for spina bifida and anencephaly separately (table 3), although observed risk reductions were small in magnitude and imprecise. Adjusting for covariates resulted in most of the estimated risks being much closer to unity (table 3). Analyses adjusted for maternal prepregnant weight, height, education, and race/ethnicity appeared to have the most substantial impact on estimated risks (table 3).

Compared with women categorized (referent) as having the lowest quartile intake of choline and having the lowest quartile intake of “total” folate (both supplements and diet combined), women whose intakes of choline were above the lowest quartile had lower, albeit imprecise, risks of NTD-affected pregnancies, irrespective of folate intake (table 4). Related analyses that investigated combined intakes of choline and methionine, and of choline and betaine, revealed that women whose intakes were highest of either methionine or of betaine in combination with choline were at the lowest risk of NTD-affected pregnancies. That is, odds ratios of 0.37 (95 percent CI: 0.18, 0.76) for choline and methionine (table 5) and 0.28 (95 percent CI: 0.12, 0.65) for choline and betaine (table 6) were observed. Investigating high intakes of all three nutrients (choline, methionine, and betaine) compared with low intakes of the three nutrients produced an even smaller odds ratio of 0.17 (95 percent CI: 0.04, 0.76) (data not shown). Data were sparse in the latter comparison as well as in some of the intake-level comparisons in tables 4, 5, and 6, resulting in many of the estimated risks being imprecise.

DISCUSSION

Our results indicate decreased NTD risks associated with maternal periconceptional diets containing choline and possibly betaine. Controlling for the potential effects of maternal intake of supplemental folic acid, dietary folate, dietary methionine, and other covariates did not substantially influence risk estimates for choline but did attenuate those for betaine. NTD risk estimates were lowest for women whose diets were rich in both choline and methionine as well as choline, betaine, and methionine. Extensive literature indicates an association between folates and NTDs (1, 2). However, the quantity of literature on other related nutrients (e.g., methionine (3)) and NTD risk is small, with the current study the first known to explore choline and betaine.

Our observation of an association between higher intakes of choline and NTD risk provides evidence to suggest that deficiencies in methyl donors may be associated with NTD risk; that is, a less-than-optimal methyl-donor supply and DNA methylation have been a suggested area for research regarding certain birth defects (28). It is known that methylation of DNA can be influenced by dietary contributions of methyl donors such as choline, folate, and methionine. Choline, folate, and methionine are highly interrelated in methyl-group metabolism, and an alteration in one affects the others (15). Thus, choline deficiency could impact folate and homocysteine metabolism (29). Other dietary parameters are also involved in DNA methylation, including vitamin B12, vitamin B6, and serine (30); these additional nutrients were not investigated in this study.

Choline is depleted in pregnant rats; therefore, an animal’s ability to obtain sufficient choline from dietary sources may be compromised during pregnancy (29, 31). Moreover, it has been observed in experimental systems that inhibiting choline uptake and metabolism in mouse embryos results in NTDs (19) and that pregnant rabbits, given anticholinergic drugs, have reduced placental and fetal choline levels and produce higher frequencies of malformed offspring (32). However, not all experiments involving choline-deficient or folate-deficient diets have revealed increased frequencies of NTD-affected offspring (32). Furthermore, choline appears to have a role in apoptosis, one that extends beyond the repletion of methyl groups (29). Regulation of apoptosis is important to the development of the neural tube (33). Thus, choline’s role in apoptosis could theoretically offer another mechanism for improper neural tube closure.

Despite this study’s population-based ascertainment of cases and controls, high maternal participation rate, large sample size, and ability to control for many relevant covariates, its ability to draw firm inferences was limited by surrogate measures of tissue concentrations of choline and betaine. Choline and betaine intakes were imputed blinded to case and control status. Thus, errors that might arise from imputation of such surrogate measures would likely be the same for mothers of both cases and controls. Therefore, misclassification errors would likely produce attenuated, rather than inflated, estimates of NTD risks. The impact on estimated risks associated with using intake data to reflect tissue concentrations is unknown, however.

In interpreting our findings, we cannot exclude the possibility that observed elevated risks were attributable to recall bias. Although there is little evidence that recall bias contributes substantially to the results of studies such as these (34), it is possible, for example, that mothers of cases overreported or mothers of controls underreported intakes of foods associated with higher choline and betaine values. Foods contributing to higher choline intakes were eggs, milk, and orange juice, whereas foods contributing to high betaine intakes were breads, spinach, and biscuits. However, most women in the study (interviewed more than 10 years ago) were probably unaware of the choline and betaine values of foods they ate. It therefore seems unlikely that differential recall between mothers of cases and mothers of controls is a probable explanation for our results. We also cannot exclude the possibility that observed elevated risks were due to random variation given the sparseness of data for some comparisons.

For more than 30 years, evidence has emerged to indicate that periconceptional nutrient intakes, particularly folate, lower risks of NTD-affected pregnancies. Although fortification of the US food supply with folic acid is associated with a decreased prevalence of NTDs (35), a substantial population burden of these serious birth defects still exists. Thus, our findings identifying other dietary components may offer additional, important clues to understanding the complex etiologies of NTDs.

ACKNOWLEDGMENTS

This research was supported by funds from Centers for Disease Control and Prevention, Centers of Excellence Award U50/CCU913241.

Reprint requests to Dr. Gary M. Shaw, California Birth Defects Monitoring Program, 1917 Fifth Street, Berkeley, CA 94710 (e-mail: gsh@cbdmp.org).

TABLE 1.

Characteristics of women with neural tube defect-affected pregnancies (cases) and those without such pregnancies (controls), California, 1989–1991

CharacteristicCasesControls
(n = 424)(n = 440)
No.%*No.%*
Race/ethnicity
White18142.723553.4
US-born Latina4911.66214.1
Foreign-born Latina15135.69220.9
Other4310.15011.4
Education
<High school graduate16438.711425.9
High school graduate16238.218040.9
>High school graduate9722.914533.0
Multivitamin use
No use16238.212027.3
Began 3 months before conception7116.77717.5
Began in first trimester18744.123553.4
MeanSD†MeanSD
Height (m)1.610.091.630.08
Prepregnant weight (kg)63.615.060.811.9
Energy intake (kcal/day)2,240.8896.52,373.2940.6
Dietary folate intake (µg/day)351.7188.7372.0198.6
Dietary methionine intake (mg/day)1,862.7830.52,037.0898.7
Choline intake (mg/day)377.3175.6408.5178.8
Betaine intake (mg/day)174.9109.4202.4127.7
CharacteristicCasesControls
(n = 424)(n = 440)
No.%*No.%*
Race/ethnicity
White18142.723553.4
US-born Latina4911.66214.1
Foreign-born Latina15135.69220.9
Other4310.15011.4
Education
<High school graduate16438.711425.9
High school graduate16238.218040.9
>High school graduate9722.914533.0
Multivitamin use
No use16238.212027.3
Began 3 months before conception7116.77717.5
Began in first trimester18744.123553.4
MeanSD†MeanSD
Height (m)1.610.091.630.08
Prepregnant weight (kg)63.615.060.811.9
Energy intake (kcal/day)2,240.8896.52,373.2940.6
Dietary folate intake (µg/day)351.7188.7372.0198.6
Dietary methionine intake (mg/day)1,862.7830.52,037.0898.7
Choline intake (mg/day)377.3175.6408.5178.8
Betaine intake (mg/day)174.9109.4202.4127.7

* Percentages may not equal 100 because of missing data or rounding.

† SD, standard deviation.

TABLE 1.

Characteristics of women with neural tube defect-affected pregnancies (cases) and those without such pregnancies (controls), California, 1989–1991

CharacteristicCasesControls
(n = 424)(n = 440)
No.%*No.%*
Race/ethnicity
White18142.723553.4
US-born Latina4911.66214.1
Foreign-born Latina15135.69220.9
Other4310.15011.4
Education
<High school graduate16438.711425.9
High school graduate16238.218040.9
>High school graduate9722.914533.0
Multivitamin use
No use16238.212027.3
Began 3 months before conception7116.77717.5
Began in first trimester18744.123553.4
MeanSD†MeanSD
Height (m)1.610.091.630.08
Prepregnant weight (kg)63.615.060.811.9
Energy intake (kcal/day)2,240.8896.52,373.2940.6
Dietary folate intake (µg/day)351.7188.7372.0198.6
Dietary methionine intake (mg/day)1,862.7830.52,037.0898.7
Choline intake (mg/day)377.3175.6408.5178.8
Betaine intake (mg/day)174.9109.4202.4127.7
CharacteristicCasesControls
(n = 424)(n = 440)
No.%*No.%*
Race/ethnicity
White18142.723553.4
US-born Latina4911.66214.1
Foreign-born Latina15135.69220.9
Other4310.15011.4
Education
<High school graduate16438.711425.9
High school graduate16238.218040.9
>High school graduate9722.914533.0
Multivitamin use
No use16238.212027.3
Began 3 months before conception7116.77717.5
Began in first trimester18744.123553.4
MeanSD†MeanSD
Height (m)1.610.091.630.08
Prepregnant weight (kg)63.615.060.811.9
Energy intake (kcal/day)2,240.8896.52,373.2940.6
Dietary folate intake (µg/day)351.7188.7372.0198.6
Dietary methionine intake (mg/day)1,862.7830.52,037.0898.7
Choline intake (mg/day)377.3175.6408.5178.8
Betaine intake (mg/day)174.9109.4202.4127.7

* Percentages may not equal 100 because of missing data or rounding.

† SD, standard deviation.

TABLE 2.

Effect estimates (odds ratios) for neural tube defect-affected pregnancies associated with maternal choline intake during the periconceptional period, California, 1989–1991

Total cholineNo. of casesNo. of controlsOdds ratio*95% CI†
All neural tube defects
Continuous measure‡4244400.900.78, 1.04
Quartile measure§
≤290.41147110Reference
290.42–371.52991100.660.45, 0.97
371.53–498.46981100.630.41, 0.98
>498.46801100.490.27, 0.90
Spina bifida
Continuous measure‡2424400.930.79, 1.09
Quartile measure§
≤290.4180110Reference
290.42–371.52561100.660.42, 1.04
371.53–498.46611100.680.41, 1.14
>498.46451100.450.22, 0.93
Anencephaly
Continuous measure‡1614400.830.67, 1.02
Quartile measure§
≤290.4159110Reference
290.42–371.52381100.640.39, 1.07
371.53–498.46331100.560.31, 1.02
>498.46311100.520.24, 1.17
Total cholineNo. of casesNo. of controlsOdds ratio*95% CI†
All neural tube defects
Continuous measure‡4244400.900.78, 1.04
Quartile measure§
≤290.41147110Reference
290.42–371.52991100.660.45, 0.97
371.53–498.46981100.630.41, 0.98
>498.46801100.490.27, 0.90
Spina bifida
Continuous measure‡2424400.930.79, 1.09
Quartile measure§
≤290.4180110Reference
290.42–371.52561100.660.42, 1.04
371.53–498.46611100.680.41, 1.14
>498.46451100.450.22, 0.93
Anencephaly
Continuous measure‡1614400.830.67, 1.02
Quartile measure§
≤290.4159110Reference
290.42–371.52381100.640.39, 1.07
371.53–498.46331100.560.31, 1.02
>498.46311100.520.24, 1.17

* Odds ratio adjusted for maternal total energy intake.

† CI, confidence interval.

‡ Odds ratio expressed as change in risk per 100 mg of change in intake.

§ Quartiles determined from intake levels for mothers of controls.

TABLE 2.

Effect estimates (odds ratios) for neural tube defect-affected pregnancies associated with maternal choline intake during the periconceptional period, California, 1989–1991

Total cholineNo. of casesNo. of controlsOdds ratio*95% CI†
All neural tube defects
Continuous measure‡4244400.900.78, 1.04
Quartile measure§
≤290.41147110Reference
290.42–371.52991100.660.45, 0.97
371.53–498.46981100.630.41, 0.98
>498.46801100.490.27, 0.90
Spina bifida
Continuous measure‡2424400.930.79, 1.09
Quartile measure§
≤290.4180110Reference
290.42–371.52561100.660.42, 1.04
371.53–498.46611100.680.41, 1.14
>498.46451100.450.22, 0.93
Anencephaly
Continuous measure‡1614400.830.67, 1.02
Quartile measure§
≤290.4159110Reference
290.42–371.52381100.640.39, 1.07
371.53–498.46331100.560.31, 1.02
>498.46311100.520.24, 1.17
Total cholineNo. of casesNo. of controlsOdds ratio*95% CI†
All neural tube defects
Continuous measure‡4244400.900.78, 1.04
Quartile measure§
≤290.41147110Reference
290.42–371.52991100.660.45, 0.97
371.53–498.46981100.630.41, 0.98
>498.46801100.490.27, 0.90
Spina bifida
Continuous measure‡2424400.930.79, 1.09
Quartile measure§
≤290.4180110Reference
290.42–371.52561100.660.42, 1.04
371.53–498.46611100.680.41, 1.14
>498.46451100.450.22, 0.93
Anencephaly
Continuous measure‡1614400.830.67, 1.02
Quartile measure§
≤290.4159110Reference
290.42–371.52381100.640.39, 1.07
371.53–498.46331100.560.31, 1.02
>498.46311100.520.24, 1.17

* Odds ratio adjusted for maternal total energy intake.

† CI, confidence interval.

‡ Odds ratio expressed as change in risk per 100 mg of change in intake.

§ Quartiles determined from intake levels for mothers of controls.

TABLE 3.

Effect estimates (odds ratios) for neural tube defect-affected pregnancies associated with maternal betaine intake during the periconceptional period, California, 1989–1991

BetaineNo. of cases*No. of controls*Odds ratio†95% CI‡Adjusted odds ratio§95% CIAdjusted odds ratio¶95% CI
All neural tube defects
Continuous measure#3914110.840.73, 0.970.870.76, 1.010.960.82, 1.12
Quartile measure**
≤119.70131103ReferenceReferenceReference
119.71–177.391061030.840.57, 1.240.910.61, 1.341.070.71, 1.61
177.40–258.36791030.640.42, 0.970.710.46, 1.080.930.60, 1.46
>258.36751020.640.41, 1.020.740.46, 1.180.990.59, 1.66
Spina bifida
Continuous measure#2244110.900.77, 1.060.940.80, 1.111.010.85, 1.21
Quartile measure**
≤119.7072103ReferenceReferenceReference
119.71–177.39631030.890.57, 1.400.950.60, 1.501.080.67, 1.73
177.40–258.36401030.570.35, 0.940.650.39, 1.070.790.46, 1.35
>258.36491020.720.42, 1.230.850.49, 1.461.080.59, 1.95
Anencephaly
Continuous measure#1494110.770.62, 0.960.790.64, 0.990.880.70, 1.10
Quartile measure**
≤119.7049103ReferenceReferenceReference
119.71–177.39381030.840.50, 1.410.880.52, 1.501.090.62, 1.90
177.40–258.36371030.850.49, 1.470.900.52, 1.571.260.70, 2.27
>258.36251020.620.33, 1.170.690.36, 1.330.930.46, 1.87
BetaineNo. of cases*No. of controls*Odds ratio†95% CI‡Adjusted odds ratio§95% CIAdjusted odds ratio¶95% CI
All neural tube defects
Continuous measure#3914110.840.73, 0.970.870.76, 1.010.960.82, 1.12
Quartile measure**
≤119.70131103ReferenceReferenceReference
119.71–177.391061030.840.57, 1.240.910.61, 1.341.070.71, 1.61
177.40–258.36791030.640.42, 0.970.710.46, 1.080.930.60, 1.46
>258.36751020.640.41, 1.020.740.46, 1.180.990.59, 1.66
Spina bifida
Continuous measure#2244110.900.77, 1.060.940.80, 1.111.010.85, 1.21
Quartile measure**
≤119.7072103ReferenceReferenceReference
119.71–177.39631030.890.57, 1.400.950.60, 1.501.080.67, 1.73
177.40–258.36401030.570.35, 0.940.650.39, 1.070.790.46, 1.35
>258.36491020.720.42, 1.230.850.49, 1.461.080.59, 1.95
Anencephaly
Continuous measure#1494110.770.62, 0.960.790.64, 0.990.880.70, 1.10
Quartile measure**
≤119.7049103ReferenceReferenceReference
119.71–177.39381030.840.50, 1.410.880.52, 1.501.090.62, 1.90
177.40–258.36371030.850.49, 1.470.900.52, 1.571.260.70, 2.27
>258.36251020.620.33, 1.170.690.36, 1.330.930.46, 1.87

* Numbers of cases and controls for whom no values were missing for any of the analyzed covariates described in the fifth (¶) footnote.

† Odds ratio adjusted for maternal total energy intake.

‡ CI, confidence interval.

§ Odds ratio adjusted for methionine intake, vitamin use, total energy intake, and dietary folate intake.

¶ Odds ratio adjusted for methionine intake, vitamin use, total energy intake, dietary folate intake, race/ethnicity, education, weight, and height.

# Odds ratio expressed as change in risk per 100 mg of change in intake.

** Quartiles determined from intake levels for mothers of controls.

TABLE 3.

Effect estimates (odds ratios) for neural tube defect-affected pregnancies associated with maternal betaine intake during the periconceptional period, California, 1989–1991

BetaineNo. of cases*No. of controls*Odds ratio†95% CI‡Adjusted odds ratio§95% CIAdjusted odds ratio¶95% CI
All neural tube defects
Continuous measure#3914110.840.73, 0.970.870.76, 1.010.960.82, 1.12
Quartile measure**
≤119.70131103ReferenceReferenceReference
119.71–177.391061030.840.57, 1.240.910.61, 1.341.070.71, 1.61
177.40–258.36791030.640.42, 0.970.710.46, 1.080.930.60, 1.46
>258.36751020.640.41, 1.020.740.46, 1.180.990.59, 1.66
Spina bifida
Continuous measure#2244110.900.77, 1.060.940.80, 1.111.010.85, 1.21
Quartile measure**
≤119.7072103ReferenceReferenceReference
119.71–177.39631030.890.57, 1.400.950.60, 1.501.080.67, 1.73
177.40–258.36401030.570.35, 0.940.650.39, 1.070.790.46, 1.35
>258.36491020.720.42, 1.230.850.49, 1.461.080.59, 1.95
Anencephaly
Continuous measure#1494110.770.62, 0.960.790.64, 0.990.880.70, 1.10
Quartile measure**
≤119.7049103ReferenceReferenceReference
119.71–177.39381030.840.50, 1.410.880.52, 1.501.090.62, 1.90
177.40–258.36371030.850.49, 1.470.900.52, 1.571.260.70, 2.27
>258.36251020.620.33, 1.170.690.36, 1.330.930.46, 1.87
BetaineNo. of cases*No. of controls*Odds ratio†95% CI‡Adjusted odds ratio§95% CIAdjusted odds ratio¶95% CI
All neural tube defects
Continuous measure#3914110.840.73, 0.970.870.76, 1.010.960.82, 1.12
Quartile measure**
≤119.70131103ReferenceReferenceReference
119.71–177.391061030.840.57, 1.240.910.61, 1.341.070.71, 1.61
177.40–258.36791030.640.42, 0.970.710.46, 1.080.930.60, 1.46
>258.36751020.640.41, 1.020.740.46, 1.180.990.59, 1.66
Spina bifida
Continuous measure#2244110.900.77, 1.060.940.80, 1.111.010.85, 1.21
Quartile measure**
≤119.7072103ReferenceReferenceReference
119.71–177.39631030.890.57, 1.400.950.60, 1.501.080.67, 1.73
177.40–258.36401030.570.35, 0.940.650.39, 1.070.790.46, 1.35
>258.36491020.720.42, 1.230.850.49, 1.461.080.59, 1.95
Anencephaly
Continuous measure#1494110.770.62, 0.960.790.64, 0.990.880.70, 1.10
Quartile measure**
≤119.7049103ReferenceReferenceReference
119.71–177.39381030.840.50, 1.410.880.52, 1.501.090.62, 1.90
177.40–258.36371030.850.49, 1.470.900.52, 1.571.260.70, 2.27
>258.36251020.620.33, 1.170.690.36, 1.330.930.46, 1.87

* Numbers of cases and controls for whom no values were missing for any of the analyzed covariates described in the fifth (¶) footnote.

† Odds ratio adjusted for maternal total energy intake.

‡ CI, confidence interval.

§ Odds ratio adjusted for methionine intake, vitamin use, total energy intake, and dietary folate intake.

¶ Odds ratio adjusted for methionine intake, vitamin use, total energy intake, dietary folate intake, race/ethnicity, education, weight, and height.

# Odds ratio expressed as change in risk per 100 mg of change in intake.

** Quartiles determined from intake levels for mothers of controls.

TABLE 4.

Effect estimates (odds ratios)* for neural tube defect-affected pregnancies according to quartile of average daily maternal dietary intake of choline and total folate in the 3 months before conception, California, 1989–1991

Quartile of choline (mg/day)Quartile of folate (µg/day)
≤246.39246.40–350.55350.56–544.36>544.36
≤290.41
No. of cases/no. of controls85/5928/2515/1019/16
Odds ratioReference0.781.050.83
95% CI†0.41, 1.480.44, 2.490.39, 1.75
290.42–371.52
No. of cases/no. of controls24/2829/3726/2120/24
Odds ratio0.600.550.880.59
95% CI0.31, 1.160.30, 1.020.44, 1.750.29, 1.18
371.53–498.46
No. of cases/no. of controls8/1620/3335/3735/24
Odds ratio0.350.430.681.05
95% CI0.14, 0.890.21, 0.870.35, 1.300.52, 2.11
>498.46
No. of cases/no. of controls0/717/1526/4237/46
Odds ratioN/A†0.820.450.60
95% CI0.34, 1.950.21, 0.960.26, 1.37
Quartile of choline (mg/day)Quartile of folate (µg/day)
≤246.39246.40–350.55350.56–544.36>544.36
≤290.41
No. of cases/no. of controls85/5928/2515/1019/16
Odds ratioReference0.781.050.83
95% CI†0.41, 1.480.44, 2.490.39, 1.75
290.42–371.52
No. of cases/no. of controls24/2829/3726/2120/24
Odds ratio0.600.550.880.59
95% CI0.31, 1.160.30, 1.020.44, 1.750.29, 1.18
371.53–498.46
No. of cases/no. of controls8/1620/3335/3735/24
Odds ratio0.350.430.681.05
95% CI0.14, 0.890.21, 0.870.35, 1.300.52, 2.11
>498.46
No. of cases/no. of controls0/717/1526/4237/46
Odds ratioN/A†0.820.450.60
95% CI0.34, 1.950.21, 0.960.26, 1.37

* Odds ratios adjusted for maternal total energy intake.

† CI, confidence interval; N/A, not applicable.

TABLE 4.

Effect estimates (odds ratios)* for neural tube defect-affected pregnancies according to quartile of average daily maternal dietary intake of choline and total folate in the 3 months before conception, California, 1989–1991

Quartile of choline (mg/day)Quartile of folate (µg/day)
≤246.39246.40–350.55350.56–544.36>544.36
≤290.41
No. of cases/no. of controls85/5928/2515/1019/16
Odds ratioReference0.781.050.83
95% CI†0.41, 1.480.44, 2.490.39, 1.75
290.42–371.52
No. of cases/no. of controls24/2829/3726/2120/24
Odds ratio0.600.550.880.59
95% CI0.31, 1.160.30, 1.020.44, 1.750.29, 1.18
371.53–498.46
No. of cases/no. of controls8/1620/3335/3735/24
Odds ratio0.350.430.681.05
95% CI0.14, 0.890.21, 0.870.35, 1.300.52, 2.11
>498.46
No. of cases/no. of controls0/717/1526/4237/46
Odds ratioN/A†0.820.450.60
95% CI0.34, 1.950.21, 0.960.26, 1.37
Quartile of choline (mg/day)Quartile of folate (µg/day)
≤246.39246.40–350.55350.56–544.36>544.36
≤290.41
No. of cases/no. of controls85/5928/2515/1019/16
Odds ratioReference0.781.050.83
95% CI†0.41, 1.480.44, 2.490.39, 1.75
290.42–371.52
No. of cases/no. of controls24/2829/3726/2120/24
Odds ratio0.600.550.880.59
95% CI0.31, 1.160.30, 1.020.44, 1.750.29, 1.18
371.53–498.46
No. of cases/no. of controls8/1620/3335/3735/24
Odds ratio0.350.430.681.05
95% CI0.14, 0.890.21, 0.870.35, 1.300.52, 2.11
>498.46
No. of cases/no. of controls0/717/1526/4237/46
Odds ratioN/A†0.820.450.60
95% CI0.34, 1.950.21, 0.960.26, 1.37

* Odds ratios adjusted for maternal total energy intake.

† CI, confidence interval; N/A, not applicable.

TABLE 5.

Effect estimates (odds ratios)* for neural tube defect-affected pregnancies according to quartile of average daily maternal dietary intake of choline and methionine in the 3 months before conception, California, 1989–1991

Quartile of choline (mg/day)Quartile of methionine (mg/day)
≤1,420.971,420.98–1,852.871,852.88–2,491.85>2,491.85
≤290.41
No. of cases/no. of controls124/8621/202/40/0
Odds ratioReference0.700.33N/A†
95% CI†0.36, 1.380.06, 1.86
290.42–371.52
No. of cases/no. of controls21/1844/6531/253/2
Odds ratio0.780.440.790.94
95% CI0.39, 1.560.27, 0.720.42, 1.480.15, 5.83
371.53–498.46
No. of cases/no. of controls3/424/2253/6118/23
Odds ratio0.500.680.540.45
95% CI0.11, 2.290.35, 1.350.31, 0.910.21, 1.00
>498.46
No. of cases/no. of controls0/22/320/2058/85
Odds ratioN/A0.410.590.37
95% CI0.07, 2.570.28, 1.280.18, 0.76
Quartile of choline (mg/day)Quartile of methionine (mg/day)
≤1,420.971,420.98–1,852.871,852.88–2,491.85>2,491.85
≤290.41
No. of cases/no. of controls124/8621/202/40/0
Odds ratioReference0.700.33N/A†
95% CI†0.36, 1.380.06, 1.86
290.42–371.52
No. of cases/no. of controls21/1844/6531/253/2
Odds ratio0.780.440.790.94
95% CI0.39, 1.560.27, 0.720.42, 1.480.15, 5.83
371.53–498.46
No. of cases/no. of controls3/424/2253/6118/23
Odds ratio0.500.680.540.45
95% CI0.11, 2.290.35, 1.350.31, 0.910.21, 1.00
>498.46
No. of cases/no. of controls0/22/320/2058/85
Odds ratioN/A0.410.590.37
95% CI0.07, 2.570.28, 1.280.18, 0.76

* Odds ratios adjusted for maternal total energy intake.

† N/A, not applicable; CI, confidence interval.

TABLE 5.

Effect estimates (odds ratios)* for neural tube defect-affected pregnancies according to quartile of average daily maternal dietary intake of choline and methionine in the 3 months before conception, California, 1989–1991

Quartile of choline (mg/day)Quartile of methionine (mg/day)
≤1,420.971,420.98–1,852.871,852.88–2,491.85>2,491.85
≤290.41
No. of cases/no. of controls124/8621/202/40/0
Odds ratioReference0.700.33N/A†
95% CI†0.36, 1.380.06, 1.86
290.42–371.52
No. of cases/no. of controls21/1844/6531/253/2
Odds ratio0.780.440.790.94
95% CI0.39, 1.560.27, 0.720.42, 1.480.15, 5.83
371.53–498.46
No. of cases/no. of controls3/424/2253/6118/23
Odds ratio0.500.680.540.45
95% CI0.11, 2.290.35, 1.350.31, 0.910.21, 1.00
>498.46
No. of cases/no. of controls0/22/320/2058/85
Odds ratioN/A0.410.590.37
95% CI0.07, 2.570.28, 1.280.18, 0.76
Quartile of choline (mg/day)Quartile of methionine (mg/day)
≤1,420.971,420.98–1,852.871,852.88–2,491.85>2,491.85
≤290.41
No. of cases/no. of controls124/8621/202/40/0
Odds ratioReference0.700.33N/A†
95% CI†0.36, 1.380.06, 1.86
290.42–371.52
No. of cases/no. of controls21/1844/6531/253/2
Odds ratio0.780.440.790.94
95% CI0.39, 1.560.27, 0.720.42, 1.480.15, 5.83
371.53–498.46
No. of cases/no. of controls3/424/2253/6118/23
Odds ratio0.500.680.540.45
95% CI0.11, 2.290.35, 1.350.31, 0.910.21, 1.00
>498.46
No. of cases/no. of controls0/22/320/2058/85
Odds ratioN/A0.410.590.37
95% CI0.07, 2.570.28, 1.280.18, 0.76

* Odds ratios adjusted for maternal total energy intake.

† N/A, not applicable; CI, confidence interval.

TABLE 6.

Effect estimates (odds ratios)* for neural tube defect-affected pregnancies according to quartile of average daily maternal dietary intake of choline and betaine in the 3 months before conception, California, 1989–1991

Quartile of choline (mg/day)Quartile of betaine (mg/day)
≤118.02118.03–175.67175.68–258.02>258.02
≤290.41
No. of cases/no. of controls84/5337/2520/196/13
Odds ratioReference0.890.620.27
95% CI†0.48, 1.660.30, 1.290.10, 0.77
290.42–371.52
No. of cases/no. of controls31/2632/3924/2912/16
Odds ratio0.690.470.460.42
95% CI0.37, 1.320.26, 0.860.23, 0.910.18, 0.99
371.53–498.46
No. of cases/no. of controls21/2225/3024/2928/29
Odds ratio0.530.450.440.49
95% CI0.25, 1.100.23, 0.900.22, 0.900.23, 1.03
>498.46
No. of cases/no. of controls6/924/1618/3332/52
Odds ratio0.350.720.260.28
95% CI0.11, 1.090.30, 1.740.11, 0.610.12, 0.65
Quartile of choline (mg/day)Quartile of betaine (mg/day)
≤118.02118.03–175.67175.68–258.02>258.02
≤290.41
No. of cases/no. of controls84/5337/2520/196/13
Odds ratioReference0.890.620.27
95% CI†0.48, 1.660.30, 1.290.10, 0.77
290.42–371.52
No. of cases/no. of controls31/2632/3924/2912/16
Odds ratio0.690.470.460.42
95% CI0.37, 1.320.26, 0.860.23, 0.910.18, 0.99
371.53–498.46
No. of cases/no. of controls21/2225/3024/2928/29
Odds ratio0.530.450.440.49
95% CI0.25, 1.100.23, 0.900.22, 0.900.23, 1.03
>498.46
No. of cases/no. of controls6/924/1618/3332/52
Odds ratio0.350.720.260.28
95% CI0.11, 1.090.30, 1.740.11, 0.610.12, 0.65

* Odds ratios adjusted for maternal total energy intake.

† CI, confidence interval.

TABLE 6.

Effect estimates (odds ratios)* for neural tube defect-affected pregnancies according to quartile of average daily maternal dietary intake of choline and betaine in the 3 months before conception, California, 1989–1991

Quartile of choline (mg/day)Quartile of betaine (mg/day)
≤118.02118.03–175.67175.68–258.02>258.02
≤290.41
No. of cases/no. of controls84/5337/2520/196/13
Odds ratioReference0.890.620.27
95% CI†0.48, 1.660.30, 1.290.10, 0.77
290.42–371.52
No. of cases/no. of controls31/2632/3924/2912/16
Odds ratio0.690.470.460.42
95% CI0.37, 1.320.26, 0.860.23, 0.910.18, 0.99
371.53–498.46
No. of cases/no. of controls21/2225/3024/2928/29
Odds ratio0.530.450.440.49
95% CI0.25, 1.100.23, 0.900.22, 0.900.23, 1.03
>498.46
No. of cases/no. of controls6/924/1618/3332/52
Odds ratio0.350.720.260.28
95% CI0.11, 1.090.30, 1.740.11, 0.610.12, 0.65
Quartile of choline (mg/day)Quartile of betaine (mg/day)
≤118.02118.03–175.67175.68–258.02>258.02
≤290.41
No. of cases/no. of controls84/5337/2520/196/13
Odds ratioReference0.890.620.27
95% CI†0.48, 1.660.30, 1.290.10, 0.77
290.42–371.52
No. of cases/no. of controls31/2632/3924/2912/16
Odds ratio0.690.470.460.42
95% CI0.37, 1.320.26, 0.860.23, 0.910.18, 0.99
371.53–498.46
No. of cases/no. of controls21/2225/3024/2928/29
Odds ratio0.530.450.440.49
95% CI0.25, 1.100.23, 0.900.22, 0.900.23, 1.03
>498.46
No. of cases/no. of controls6/924/1618/3332/52
Odds ratio0.350.720.260.28
95% CI0.11, 1.090.30, 1.740.11, 0.610.12, 0.65

* Odds ratios adjusted for maternal total energy intake.

† CI, confidence interval.

References

1.

Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation.

N Engl J Med
1992
;
327
:
1832
–5.

2.

Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group.

Lancet
1991
;
338
:
131
–7.

3.

Shaw GM, Velie EM, Schaffer D. Is dietary intake of methionine associated with a reduction in risk for neural tube defect-affected pregnancies?

Teratology
1997
;
56
:
295
–9.

4.

Velie EM, Block G, Shaw GM, et al. Maternal supplemental and dietary zinc intake and the occurrence of neural tube defects in California.

Am J Epidemiol
1999
;
150
:
605
–16.

5.

Schorah CJ, Wild J, Hartley R, et al. The effect of periconceptional supplementation on blood vitamin concentrations in women at recurrence risk for neural tube defect.

Br J Nutr
1983
;
49
:
203
–11.

6.

Shaw GM, Todoroff K, Schaffer DM, et al. Periconceptional nutrient intake and risk for neural tube defect-affected pregnancies.

Epidemiology
1999
;
10
:
711
–16.

7.

Suarez L, Hendricks K, Felkner M, et al. Maternal serum B12 levels and risk for neural tube defects in a Texas-Mexico border population.

Ann Epidemiol
2003
;
13
:
81
–8.

8.

Friel JK, Frecker M, Fraser FC. Nutritional patterns of mothers of children with neural tube defects in Newfoundland.

Am J Hum Genet
1995
;
55
:
195
–9.

9.

Becerra JE, Khoury MJ, Cordero JF, et al. Diabetes mellitus during pregnancy and the risks for specific birth defects: a population-based case-control study.

Pediatrics
1990
;
85
:
1
–9.

10.

Hendricks KA, Nuno OM, Suarez L, et al. Effects of hyperinsulinemia and obesity on risk of neural tube defects among Mexican Americans.

Epidemiology
2001
;
12
:
630
–5.

11.

Waller DK, Mills JL, Simpson JL, et al. Are obese women at higher risk for producing malformed offspring?

Am J Obstet Gynecol
1994
;
170
:
541
–8.

12.

Werler MM, Louik C, Shapiro S, et al. Prepregnant weight in relation to risk of neural tube defects.

JAMA
1996
;
275
:
1089
–92.

13.

Shaw GM, Velie EM, Schaffer D. Risk of neural tube defect-affected pregnancies among obese women.

JAMA
1996
;
275
:
1093
–6.

14.

Zeisel SH. Choline: needed for normal development of memory.

J Am Coll Nutr
2000
;
19
:
528S
–531S.

15.

Shronts EP. Essential nature of choline with implications for total parenteral nutrition.

J Am Diet Assoc
1997
;
97
:
639
–49.

16.

Mason JB. Biomarkers of nutrient exposure and status in one-carbon (methyl) metabolism.

J Nutr
2003
;
133
:
941S
–7S.

17.

Institute of Medicine. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, panothenic acid, biotin, and choline. Washington, DC: National Academies Press, 1998:1–20.

18.

Steegers-Theunissen RP, Boers GH, Trijbels FJ, et al. Maternal hyperhomocysteinemia: a risk factor for neural-tube defects?

Metabolism
1994
;
43
:
1475
–80.

19.

Fisher MC, Zeisel SH, Mar MH, et al. Inhibitors of choline uptake and metabolism cause developmental abnormalities in neuralating mouse embryos.

Teratology
2001
;
64
:
114
–22.

20.

Shaw GM, Schaffer D, Velie EM, et al. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects.

Epidemiology
1995
;
6
:
219
–26.

21.

Block G, Hartman AM, Dresser CM, et al. A data-based approach to diet questionnaire design and testing.

Am J Epidemiol
1986
;
124
:
453
–69.

22.

Mares-Perlman JA, Klein BE, Klein R, et al. A diet history questionnaire ranks nutrient intakes in middle-aged and older men and women similarly to multiple food records.

J Nutr
1993
;
123
:
489
–501.

23.

Block G, Thompson FE, Hartman AM, et al. Comparison of two dietary questionnaires validated against multiple dietary records collected during a 1-year period.

J Am Diet Assoc
1992
;
92
:
686
–93.

24.

Block G, Woods M, Potosky A, et al. Validation of a self-administered diet history questionnaire using multiple diet records.

J Clin Epidemiol
1990
;
43
:
1327
–35.

25.

Zeisel SH, Mar MH, Howe JC, et al. Concentrations of choline-containing compounds and betaine in common foods.

J Nutr
2003
;
133
:
1302
–7.

26.

Zeisel SH, Mar MH, Howe JC, et al. Concentrations of choline-containing compounds and betaine in common foods. (Erratum).

J Nutr
2003
;
133
:
2918
–19.

27.

SAS Institute, Inc. Statistical Analysis Software (SAS), release 8.2. Cary, NC: SAS Institute, Inc, 1999.

28.

Van den Veyver I. Genetic effects of methylation diets.

Annu Rev Nutr
2002
;
22
:
255
–82.

29.

Zeisel SH. Choline: essential for brain development and function.

Adv Pediatr
1997
;
44
:
263
–95.

30.

Slattery ML, Schaffer D, Edwards SL, et al. Are dietary factors involved in DNA methylation associated with colon cancer?

Nutr Cancer
1997
;
28
:
52
–62.

31.

Zeisel SH, Mar MH, Zhou Z, et al. Pregnancy and lactation are associated with diminished concentrations of choline and its metabolites in rat liver.

J Nutr
1995
;
125
:
3049
–54.

32.

McBride WG, Hicks LJ. Acetylcholine and choline levels in rabbit fetuses exposed to anticholinergics.

Int J Dev Neurosci
1987
;
5
:
117
–25.

33.

Harris MJ, Juriloff DM. Mini-review: toward understanding mechanisms of genetic neural tube defects in mice.

Teratology
1999
;
60
:
292
–5.

34.

Swan SH, Shaw GM, Schulman J. Reporting and selection bias in case-control studies of congenital malformations.

Epidemiology
1992
;
4
:
356
–63.

35.

Williams LJ, Mai CT, Edmonds LD, et al. Prevalence of spina bifida and anencephaly during the transition to mandatory folic acid fortification in the United States.

Teratology
2002
;
66
:
33
–9.